Mergers and Acquisitions

Syntegon Acquires Telstar

June 11, 2024

Syntegon will expand its processing and packaging by acquiring the Spanish equipment supplier.

Johnson & Johnson to Acquire Global Rights to Numab Therapeutics’ Bispecific Antibody for Atopic Dermatitis in $1.25 Billion Deal

May 30, 2024

Johnson & Johnson will gain NM26, a bispecific antibody targeting atopic dermatitis, via the acquisition of a wholly owned subsidiary of Numab Therapeutics.

Merck KGaA Announces $600 Million Deal to Acquire Mirus Bio

May 24, 2024

With this acquisition, Merck KGaA will have the capability to offer integrated services for viral vector manufacturing.

A Look at the Future of Bio/Pharma Partnerships at the US Pharma and Biotech Summit

May 17, 2024

Ken Keller, president and CEO, Daiichi Sankyo, discusses the foundation of partnership and takes a look at the future of biotech partnerships at the US Pharma and Biotech Summit.

US Federal Trade Commission Seeks Additional Information on Novo Nordisk Parent-Catalent Deal

May 06, 2024

The request for more information was received weeks after an application to the FTC was refiled to approve the deal.

Cormica Announces Seven-Figure Acquisition of TPM Laboratories

May 03, 2024

Cormica’s first US Acquisition is intended to support to organic growth of TPM laboratories.

Santander UK Grants £30 Million Loan Package to Ennogen Healthcare

May 03, 2024

The loan is intended to support Ennogen’s growth as it looks to international acquisitions.

Genmab Expands ADC Pipeline with $1.8 Billion Acquisition of ProfoundBio

April 04, 2024

Genmab's acquisition of ProfoundBio will boost its clinical and preclinical pipeline of ADCs for targeted cancer treatment.

AbbVie Gains Landos Biopharma and Full FDA Approval for ADC Product

March 28, 2024

The Landos acquisition adds a lead asset in autoimmune and inflammatory disease to AbbVie's portfolio, while the company's ADC, ELAHERE, gets full FDA approval.

Roche Sells Large-Scale Biologics Manufacturing Site in US to Lonza for $1.2 Billion

March 26, 2024

The Vacaville, Calif., site acquisition gives Lonza one of the largest biologics manufacturing sites for mammalian cell-based therapies worldwide.